iPhone Omnia.png

About

We’re Changing the Way the World Thinks About Diabetes 

OMNIA is an artificial pancreas system, which helps people to stay in safe glucose range and avoid any complications associated with diabetes. 

It's an app built with unique neural network powered algorithm with very easy setup process and configuration. 

With OMNIA its very easy to achieve more than 70% TiR* and make life with diabetes much more easier.

* TIR or Time in range - time in the target range of 3.9-10 mmol / L (70-180 mg / dL).

iPhone Omnia.png

Diabetes become pandemic

Diabetes is a chronic, metabolic disease characterised by elevated levels of blood glucose (or blood sugar), which leads over time to serious damage to the heart, blood vessels, eyes, kidneys and nerves.

 

537 million adults (20-79 years) are living with diabetes - 1 in 10. This number is predicted to rise to 643 million by 2030 and 783 million by 2045.

 

Diabetes is responsible for 6.7 million deaths in 2021 - 1 every 5 seconds.

20% of people with diabetes have insulin-dependent diabetes, which need automated solution for insulin calculation and delivery like OMNIA.

OMNIA is a must-have app for about 100 mln people with insulin-dependent diabetes, which helps them to get easier, better and healthier life.

Sources: The WHO (World Health Organization) & IDF (International Diabetes Federation).

Diabetes.png

537 million adults have Diabetes

~100 million have insulin-dependent Diabetes

What makes OMNIA superior?

Time in range
Internal test and simulation reached 84% average TiR**

Plus.png
Galaxy.png
Plus.png
Plus.png

*84% Average Time in range* among the all groups (children, adolescents and adults) during pre-clinical trials
** Time in range - time in the target range of 3.9-10 mmol / L (70-180 mg / dL).

Ease of use
Quick and intuitive setup. No competences required. No specialist needed for daily management

System adaptivity
Algorithm powered by neural networks adapts to key parameters of each individual user

OMNIA pre-clinical study and internal tests results showed incredible results not only in TIR but also in Hypoglycaemia cases, one of the most clinical indicator for people with diabetes.

OMNIA compared with only 2 commercially available solutions in EU:

Comparison.png

*84% Average Time in range* among the all groups (children, adolescents and adults) during pre-clinical trials
** Time in range - time in the target range of 3.9-10 mmol / L (70-180 mg / dL).

Sources - https://camdiab.com, https://www.diabeloop.com, https://clinicaltrials.gov/, https://www.thelancet.com 

Market Potential

In 2021, 966 billions USD was spent on diabetes worldwide*.

Average cost of APS solution for healthcare system is 80$ for each user per month

Existing APS solutions covers less than 1% of the market.

USA

flag-united-states-3012.png

7.000.000 

potential APS users

~ $ 540M per month

 

379.5 billions USD was spent on diabetes in 2021

EU

1f1ea-1f1fa.png

8.800.000
potential APS users

~ $ 704M per month

189.3 billions USD was spent on diabetes in 2021

Screenshot 2022-02-17 at 16.38.04.png

APS market size

Similar projects valuation growth, mln euros

Growth.jpg
Devices.jpg

Strategy & next steps

OMNIA team is aiming to complete EU clinical trials in 2022 and take 10-20% of market in 2023.

  • EU clinical trials
    Starts in Q2 2022 in Austria under supervising of University of Graz.
     

  • EU CE mark
    Completing European certification process.
     

  • Commercial available product
    Launch commercial product in 2023 (
    subscriptions, social security integration, licensing and other options for big med-tech companies).
     

  • FDA 
    Future investment rounds & income will allow us to start FDA clearance process in the USA and reach more markets (USA, India, Asia).
     

  • iOS, SmartWatch, Web
    Making AI APS work on all the platforms to reach maximum users (iOS, Android Wear, Web interface etc).
     

  • Partners & collabs
    Adding new pumps, pens & sensors to fit more users

Team

JM.jpg

Julia Mader

Head of Science

  • Associate Professor of Medicine at the Division of Endocrinology and Diabetology at Medical University of Graz, Austria

JMA_edited.png

Jean-Marc Azoulay

CBDO

  • 30 years of experience in consulting, strategic planning, and operational management

  • General Director in Bain Company, AT Kearney and Telesis

EY.JPG

Evgeny Yundin

Chief Product

  • 8 years of experience in marketing

  • More than 50 successful digital projects for L'Oreal Paris, Diageo, Lukoil, BMW, TetraPak

Denis.jpg

Denis Romashov

CEO

  • Asset manager with 10 years of experience 

  • Investor in 11 startups 

Vitaly.jpg

Vitaly Fedotov

Chief tech officer

  • Engineer - programmer with 12 years of experience 

  • Tech lead of the algorithm 

Alexey.jpg

Alexey Dedeshko

COO

  • 50 proven diabetes management strategies

  • 5 years of experience with 4 artificial pancreas

Round & conditions

€ 2M

€ 30M

Pre-A round amount

Pre-money valuation

OMNIA goal for current Pre-A round is to raise 2 mln euros. 

The money from the round will be used for purchasing equipment (pumps & sensors), conducting clinical trials in Europe, obtaining CE mark and development support.

OMNIA shareholders will consider various options for attracting investments, including grants,  sale of part of the company's shares and options. Please contact us for more information.

Contact us

• 92200, Paris,
Neuilly Sur Seine

• 121205, Moscow, 
Skolkovo Innovation Center